To exploit the beneficial effects while compensating for hyperglycemic effects, GLP-1 and glucagon coagonists are already being clinically tested for the treatment of diabetes and non-alcoholic steatohepatitis. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.